CL2009000138A1 - Process of elaboration of an ozonized composition that consists of three phases and includes a double process of ozonation of one or more of its natural and / or synthetic raw materials; Useful to oxygenate, nourish, hydrate, repair and generate cell tissue. - Google Patents

Process of elaboration of an ozonized composition that consists of three phases and includes a double process of ozonation of one or more of its natural and / or synthetic raw materials; Useful to oxygenate, nourish, hydrate, repair and generate cell tissue.

Info

Publication number
CL2009000138A1
CL2009000138A1 CL2009000138A CL2009000138A CL2009000138A1 CL 2009000138 A1 CL2009000138 A1 CL 2009000138A1 CL 2009000138 A CL2009000138 A CL 2009000138A CL 2009000138 A CL2009000138 A CL 2009000138A CL 2009000138 A1 CL2009000138 A1 CL 2009000138A1
Authority
CL
Chile
Prior art keywords
ozonized
raw materials
composition
elaboration
repair
Prior art date
Application number
CL2009000138A
Other languages
Spanish (es)
Inventor
Tapia Patricia Alejandra Rojas
Original Assignee
Tapia Patricia Alejandra Rojas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tapia Patricia Alejandra Rojas filed Critical Tapia Patricia Alejandra Rojas
Priority to CL2009000138A priority Critical patent/CL2009000138A1/en
Publication of CL2009000138A1 publication Critical patent/CL2009000138A1/en
Priority to PCT/CL2010/000004 priority patent/WO2010083622A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCESO DE ELABORACION DE COMPOSICIONES  OZONIZADAS, REALIZADAS CON UN DOBLE PROCESO DE OZONIZACION, EL CUAL CONSTA DE TRES FASES DE ELABORACION: FASE (I): PRIMERA OZONIZACION, DONDE SE OZONIZA A UNA O MAS MATERIAS PRIMAS NATURALES Y/O SINTETICAS EN FORMA INDIVIDUAL, SIN DEJAR QUE ESTAS MATERIAS PRIMAS OZONIZADAS SE SATUREN; FASE (II): SE MEZCLAR LAS MATERIAS PRIMAS YA OZONIZADAS, CON UNA O MAS MATERIAS PRIMAS NO OZONIZADAS, HASTA FORMAR UNA COMPOSICION HOMOGENEA; FASE (III): SEGUNDA OZONIZACION, OZONIZAR A LA COMPOSICION, PARA OBTENER LA COMPOSICION OZONIZADA, LO QUE GENERA UNA MAYOR  CONCENTRACION DE OXIGENO BIOACTIVO, QUE ESTIMULA Y ACTIVA SIMULTANEAMENTE LA OXIGENACION, NUTRICION E HIDRATACION DEL TEJIDO CELULAR, FAVORECIENDO ASI LOS PROCESOS NATURALES DE REPARACION Y REGENERACION DEL TEJIDO CELULAR EN GENERAL.PROCESS OF ELABORATION OF OZONIZED COMPOSITIONS, CARRIED OUT WITH A DOUBLE OZONIZATION PROCESS, WHICH CONSISTS OF THREE PHASES OF ELABORATION: PHASE (I): FIRST OZONIZATION, WHERE OZONIZED TO ONE OR MORE NATURAL AND SYNTHETIC RAW MATERIALS, WITHOUT LETTING THESE OZONIZED RAW MATERIALS SATURATE; PHASE (II): THE OZONIZED RAW MATERIALS ARE MIXED, WITH ONE OR MORE NOT OZONIZED RAW MATERIALS, UNTIL FORMING A HOMOGENOUS COMPOSITION; PHASE (III): SECOND OZONIZATION, OZONIZE TO COMPOSITION, TO OBTAIN OZONIZED COMPOSITION, WHICH GENERATES A GREATER CONCENTRATION OF BIOACTIVE OXYGEN, THAT STIMULATES AND ACTIVATES SIMULTANEOUSLY, NUTRITION AND PROCESSING, REPAIR AND REGENERATION OF CELL TISSUE IN GENERAL.

CL2009000138A 2009-01-23 2009-01-23 Process of elaboration of an ozonized composition that consists of three phases and includes a double process of ozonation of one or more of its natural and / or synthetic raw materials; Useful to oxygenate, nourish, hydrate, repair and generate cell tissue. CL2009000138A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2009000138A CL2009000138A1 (en) 2009-01-23 2009-01-23 Process of elaboration of an ozonized composition that consists of three phases and includes a double process of ozonation of one or more of its natural and / or synthetic raw materials; Useful to oxygenate, nourish, hydrate, repair and generate cell tissue.
PCT/CL2010/000004 WO2010083622A1 (en) 2009-01-23 2010-01-22 Double ozonisation process in ozonised compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2009000138A CL2009000138A1 (en) 2009-01-23 2009-01-23 Process of elaboration of an ozonized composition that consists of three phases and includes a double process of ozonation of one or more of its natural and / or synthetic raw materials; Useful to oxygenate, nourish, hydrate, repair and generate cell tissue.

Publications (1)

Publication Number Publication Date
CL2009000138A1 true CL2009000138A1 (en) 2009-05-29

Family

ID=42355472

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000138A CL2009000138A1 (en) 2009-01-23 2009-01-23 Process of elaboration of an ozonized composition that consists of three phases and includes a double process of ozonation of one or more of its natural and / or synthetic raw materials; Useful to oxygenate, nourish, hydrate, repair and generate cell tissue.

Country Status (2)

Country Link
CL (1) CL2009000138A1 (en)
WO (1) WO2010083622A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2669988B1 (en) * 2016-11-28 2019-02-04 Tallon Francisco Javier Hidalgo PROCEDURE FOR THE ELABORATION OF A REPAIR COSMETIC PRODUCT AND PRODUCT OBTAINED

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451480A (en) * 1982-04-16 1984-05-29 James Howard Brown Method of treating acne using ozonized materials
CU23467A1 (en) * 2002-04-08 2009-12-17 Cnic Ct Nac Investigaciones PROCEDURE FOR OBTAINING OZONIZED VEGETABLE OILS AND FATS FOR PHARMACEUTICAL AND COSMETOLOGICAL PURPOSES
ITFE20060032A1 (en) * 2006-11-06 2008-05-07 Istituto Fitofarmaceutico Euga PROCEDURE FOR THE PREPARATION OF OZONIZED TERPENES, TERPENOIDS AND ESSENTIAL OILS AND APPLICATION OF THESE PRODUCTS WITH PHARMACOLOGICAL AND COSMETIC PURPOSES

Also Published As

Publication number Publication date
WO2010083622A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
CY1119660T1 (en) ANTIBAKTHPIAKH FROM THEIR ORAL COMPOSITION
CL2019001553A1 (en) Cystic fibrosis transmembrane conductance regulator modulator, pharmaceutical compositions, treatment methods and process for producing the modulator.
BR112017020952A2 (en) cancer treatment method, composition and use of composition
EA200800451A1 (en) TREATMENT OF DIHYDROPYRIDINE BLOCKERS OF CALCIUM CHANNELS AND FATTY ACIDS OF OMEGA-3 AND THEIR COMBINED PRODUCT
CL2016002367A1 (en) An oral care composition comprising a calcium carbonate treated by surface reaction.
CO6170360A2 (en) PIRIMIDINIL DERIVATIVES - PIRIDAZINONA
GT201400043A (en) IMIDAZOPIRIDAZINAS REPLACED WITH AMINO
GB2531952A (en) SC-ß cells and compositions and methods for generating the same
CL2011000668A1 (en) Compounds derived from pyrazolopyridine; Preparation process; Pharmaceutical composition and use in the treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, among others.
SV2011003855A (en) HETEROARILOS SUBSTITUTED
CR8823A (en) METHODS AND COMPOSITIONS FOR WOUND CICATRIZATION
CL2008003846A1 (en) Use of compounds derived from 1,2,4-triazolo fused with heterocycles, which act as ligands of the androgen receptor (ar); compounds; Preparation process; Pharmaceutical composition and the use of said compounds for the treatment of prostate cancer.
DOP2013000105A (en) DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINA SUBSTITUTED WITH AMINOALCOHOLES THAT ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
UY33886A (en) C-17 AND C-3 TRITERPENOIDS MODIFIED WITH INHIBITING ACTIVITY OF HIV MATURATION
CL2008001335A1 (en) Compounds derived from pyrrolopyrimidin-7-one, purine receptor antagonists p2x; preparation of these; pharmaceutical composition that includes them; process of preparation of intermediary compounds and uses in the treatment of pain, overactive bladder, among others.
UY31497A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
MY162579A (en) Micronized caco3 slurry injection system for the remineralization of desalinated and fresh water
CY1112724T1 (en) COUNCULIDINE CARBON PRODUCERS AND THE MEDICAL COMPOSITION thereof
CL2009000309A1 (en) Aromatic fluoroglycoside derivatives, pharmaceutical composition containing these compounds, procedure to prepare it and its use in the treatment of type 1 and type 2 diabetes.
UY32359A (en) PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS TO TREAT AGING DISEASES
CL2011001427A1 (en) Compounds derived from 4-azetidinyl-1-heteroaryl-cyclohexanol; pharmaceutical composition; and use in the treatment of diseases such as epoc, atherosclerosis, rheumatoid arthritis, among others.
CY1113743T1 (en) ISOCINOLINONE PRODUCTS AS COMPONENTS TOY NK3
MX2017016102A (en) Biocide composition and method.
MX2015011883A (en) Azeotropic compositions of 1,1,3,3-tetrachloroprop-1-ene and hydrogen fluoride.
PA8797801A1 (en) USE OF 2-SULPHONYLAMINOBENZOIC ACID N-PHENYLAMIDES REPLACED WITH SULFONYL IN PAIN TREATMENT